Streetbeat News

Stock Prices

BKYI

BPTS

CHRS

MDNA

MIRO

NVVE

UTHR

VXRT

WTER

Several stocks are experiencing significant pre-market movements. United Therapeutics Corporation has agreed to acquire Miromatrix Medical for $3.25 per share, causing Miromatrix's shares to jump 232%. Coherus BioSciences and Junshi Biosciences have received FDA approval for LOQTORZI, leading to a 16.2% rise in Coherus' shares. Biophytis S.A. has signed a partnership agreement with Innovation Solutions Pharma, causing its shares to rise 12.7%. On the other hand, Biophytis, The Alkaline Water Company, Medicenna Therapeutics, Nuvve Holding, and Vaxart are among the companies whose shares have fallen in pre-market trading.

Portfolio Pulse from Lisa Levin

October 30, 2023 | 12:44 pm

DAWN

Day One Biopharmaceuticals announced that the FDA has accepted its New Drug Application (NDA) for tovorafenib, a treatment for relapsed or progressive pediatric low-grade glioma. The FDA has granted priority review and assigned a Prescription Drug User Fee Act (PDUFA) date of April 30, 2024. This news has led to a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:43 pm

PCRFY

TSLA

Panasonic Holdings Corp reported a 1% Y/Y sales growth in H1 FY24, with strong performance in the Automotive and Connect segments. However, the company lowered its FY24 revenue and operating profit outlook due to deteriorating market conditions and the impact of the U.S. IRA Tax Credit accounting treatment. The energy segment, which supplies Tesla Inc, also saw a reduction in its full-year operating profit forecast.

Portfolio Pulse from Lekha Gupta

October 30, 2023 | 12:41 pm

XPO

XPO Logistics shares are trading higher following the company's Q3 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:40 pm

SRC

Realty Income has agreed to acquire Spirit Realty Capital in a $9.3 billion all-stock transaction. This has led to an increase in Spirit Realty Capital's share prices.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:39 pm

VRDN

Viridian Therapeutics has appointed Stephen Mahoney as its new CEO and announced a $185M private placement financing. The company also unveiled its next-generation FcRn inhibitor programs for autoimmune diseases. Viridian's pipeline includes IGF-1R inhibitors for thyroid eye disease (TED) and FcRn inhibitors. The company expects to select its lead subcutaneous IGF-1R program by the end of 2023 and topline results from the first THRIVE Phase 3 clinical trial for intravenous VRDN-001 for active TED in mid-2024. The financing will extend the company's operating runway into 2026.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:38 pm

AUPH

CNHI

CTRA

SMCI

SYM

Jim Cramer shared his views on several stocks on CNBC's 'Mad Money Lightning Round'. He said BP is 'not great, not bad' and he's sticking with Coterra Energy. He recommended Super Micro Computer and suggested waiting for CNH Industrial's earnings report. He expressed lack of confidence in Aurinia Pharmaceuticals and suggested avoiding General Motors. He recommended buying Boeing and waiting for Symbotic's earnings.

Portfolio Pulse from Lisa Levin

October 30, 2023 | 12:37 pm

BSQR

ESMT

PCTI

SPLK

The article lists four tech stocks that are considered overbought and may collapse in October. These include EngageSmart (ESMT), Splunk (SPLK), BSQUARE (BSQR), and PCTEL (PCTI). All four companies are in the process of being acquired by other firms.

Portfolio Pulse from Lisa Levin

October 30, 2023 | 12:35 pm

ON Semiconductor reported Q3 financial results and issued Q4 adjusted EPS and revenue guidance below estimates, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:34 pm

WDC

Western Digital (WDC) anticipates a one-time GAAP-only charge due to a separation transaction during periods preceding closing.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:30 pm